These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17337182)

  • 61. Efficacy of DA-8159, a new PDE5 inhibitor, for inducing penile erection in rabbits with acute spinal cord injury.
    Ahn BO; Kang KK; Ahn GJ; Kwon JW; Kim WB; Kang KS; Lee YS
    Int J Impot Res; 2003 Dec; 15(6):405-11. PubMed ID: 14671658
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction.
    Salem EA; Kendirci M; Hellstrom WJ
    Curr Opin Investig Drugs; 2006 Jul; 7(7):661-9. PubMed ID: 16869121
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Microarray analysis of gene expression profile in the corpus cavernosum of hypercholesterolemic rats after chronic treatment with PDE5 inhibitor.
    Jung HG; Shin JH; Kim KW; Yu JY; Kang KK; Ahn BO; Kwon JW; Yoo M
    Life Sci; 2007 Jan; 80(7):699-708. PubMed ID: 17137605
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
    Mushlin P; Boerth RC; Wells JN
    Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531
    [No Abstract]   [Full Text] [Related]  

  • 65. A case of erectile dysfunction and risk factors for coronary artery disease.
    Kloner RA
    Int J Impot Res; 2005 Dec; 17 Suppl 1():S7-S11. PubMed ID: 16391547
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
    Margo CE; French DD
    Am J Ophthalmol; 2007 Mar; 143(3):538-9. PubMed ID: 17317413
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phosphodiesterase type 5 inhibitors: state of the therapeutic class.
    Carson CC
    Urol Clin North Am; 2007 Nov; 34(4):507-15, vi. PubMed ID: 17983891
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.
    Nagendran J; Archer SL; Soliman D; Gurtu V; Moudgil R; Haromy A; St Aubin C; Webster L; Rebeyka IM; Ross DB; Light PE; Dyck JR; Michelakis ED
    Circulation; 2007 Jul; 116(3):238-48. PubMed ID: 17606845
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vitro inhibition of human cGMP-specific phosphodiesterase-5 by polyphenols from red grapes.
    Dell'Agli M; Galli GV; Vrhovsek U; Mattivi F; Bosisio E
    J Agric Food Chem; 2005 Mar; 53(6):1960-5. PubMed ID: 15769121
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors.
    Maw GN; Allerton CM; Gbekor E; Million WA
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1425-8. PubMed ID: 12668004
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mechanism of tissue-selective drug action in the cardiovascular system.
    Barrett TD; Triggle DJ; Walker MJ; Maurice DH
    Mol Interv; 2005 Apr; 5(2):84-93. PubMed ID: 15821157
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.
    Forfia PR; Lee M; Tunin RS; Mahmud M; Champion HC; Kass DA
    J Am Coll Cardiol; 2007 Mar; 49(10):1079-88. PubMed ID: 17349888
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?
    Oliver JJ
    Int J Clin Pract; 2006 Sep; 60(9):1026-7. PubMed ID: 16939541
    [No Abstract]   [Full Text] [Related]  

  • 74. Commentary on apomorphine versus sildenafil for erectile dysfunction.
    Carson CC
    J Urol; 2008 May; 179(5 Suppl):S95-6. PubMed ID: 18405768
    [No Abstract]   [Full Text] [Related]  

  • 75. Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: Methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533).
    Choi H; Lee J; Kim YH; Im DS; Hwang IC; Kim SJ; Moon SK; Lee HW; Lee SS; Ahn SK; Kim SW; Choi NS; Lee KJ
    Bioorg Med Chem Lett; 2010 Jan; 20(1):383-6. PubMed ID: 19906530
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?
    Kass DA
    Circulation; 2007 Jul; 116(3):233-5. PubMed ID: 17638937
    [No Abstract]   [Full Text] [Related]  

  • 77. [Novel indications for phosphodiesterase type 5 inhibitors].
    Rosenkranz S; Caglayan E; Erdmann E
    Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and thromboxane synthesis inhibitory activities.
    Lee SJ; Konishi Y; Yu DT; Miskowski TA; Riviello CM; Macina OT; Frierson MR; Kondo K; Sugitani M; Sircar JC
    J Med Chem; 1995 Sep; 38(18):3547-57. PubMed ID: 7658441
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Therapeutic efficacy of a course administration of vardenafil--inhibitor of phosphodiesterase-5--in erectile dysfunction].
    Aliaev IuG; Vinarov AZ; Akhvlediani ND
    Urologiia; 2007; (1):45-6, 49. PubMed ID: 17471999
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.